Overall Cost of DMTs Stable 2018–2020, Study Finds
The overall cost of disease-modifying therapies for multiple sclerosis (MS) in the U.S. remained stable from 2018 to 2020,…
Articles by Marta Figueiredo, PhD
Tecfidera, Gilenya and Ocrevus Losing Favor as Switch Therapies in US, Spherix Finds
Tecfidera (dimethyl fumarate), Gilenya (fingolimod), and Ocrevus (ocrelizumab) are losing ground to more recent therapies among U.S. multiple sclerosis (MS)…
Protecting Myelin-producing Cells From Inflammation May Be Key to Treating MS
Prolonging a cellular defense mechanism shown to restore myelin — the protective sheath around nerve cell fibers that is lost…
Kesimpta Approved in EU as At-home Injectable Therapy for Relapsing MS
The European Commission has approved Novartis’ Kesimpta (ofatumumab) as the first self-administered, at-home B-cell-targeting therapy for adults with relapsing…
More Trials Needed to Clarify Benefits of Alzheimer’s Therapy Memantine in MS
Treatment of up to a year with memantine — an approved therapy for Alzheimer’s disease — failed to prevent cognitive decline…
NMSS Partnership Targets Autoimmune Disease Research
The National Multiple Sclerosis Society has joined forces with the diabetes-focused JDRF and the Lupus Research Alliance…
Imcyse Raises €21.3M to Advance Treatments for MS, Other Diseases
Imcyse has raised €21.3 million ($25.8 million) in funding to advance its innovative immunotherapy platform for the treatment of…
AI-powered Robotic Glove May Help Improve Hand Grip Strength
BioLiberty, a Scottish biotech startup, has developed a robotic glove that uses artificial intelligence (AI) to improve the hand…
Drop in PML With Tysabri Use in Sweden Likely Due to Risk Management Plan
The number of cases of Tysabri (natalizumab) that are associated with progressive multifocal leukoencephalopathy (PML) — a serious brain…
MS-linked Molecule IL-17 Impaired Immune Cells in Mice’s Brains
Sustained, excessive levels of interleukin 17A (IL-17A) — a pro-inflammatory molecule linked to multiple sclerosis (MS) and other autoimmune diseases…
Rituximab Before or During Pregnancy Not Linked to Major Complications
Treatment with rituximab before or during pregnancy was not associated with major pregnancy or infant complications, according to a case…
National MS Society Urges DMT Dosing Changes for COVID-19 Vaccinations
To potentially increase the effectiveness of COVID-19 vaccines in people with multiple sclerosis (MS), the National Multiple Sclerosis Society…
Tecfidera Safe and Effective Over Long Term in Children With RRMS, Trial Shows
Long-term treatment with Tecfidera (dimethyl fumarate) safely and effectively reduces the frequency of relapses in children with relapsing-remitting multiple sclerosis…
Mouse Study Links Cortical Inflammation to Immune Cell Destruction
Multiple sclerosis (MS)-associated inflammation in the cerebral cortex — the outermost layer of the brain that is involved in…
Innodem to Advance Way of Diagnosing, Tracking MS via Eye Movement
Innodem Neurosciences received $6 million to advance its digital biomarker eye-tracking technology as a possible way of diagnosing and monitoring…
#ACTRIMS2021 – Forum to Focus on Several MS-related Spectrums
The upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum will focus on the spectrums of…
SERPINA3 Nerve Injury-induced Protein May Be Biomarker of PPMS
People with primary progressive multiple sclerosis (PPMS) have significantly higher levels of a nerve injury-induced protein, called SERPINA3, in…
Ocrevus Targets Pro-inflammatory T-cells, Not Just B-cells, in PPMS, Study Finds
In addition to significantly reducing subsets of B-cells — its main immune cell target — Ocrevus (ocrelizumab) lessens pro-inflammatory…
Tonix Files for Patent for TNX-1500 to Treat Autoimmune Diseases
Tonix Pharmaceuticals has filed a patent application with the World Intellectual Property Organization covering the use of TNX-1500 —…
Sexual Dysfunction Common in Men with MS, Review Finds
Sexual dysfunction affects more than 60% of adult men with multiple sclerosis (MS), according to a review study.
New Technique May Help Isolate, Characterize T-cells in MS Research
Scientists at the UCLA Broad Stem Cell Research Center have developed a technique able to more efficiently isolate specific T-cells…
BioNTech Vaccine Treats MS in Mice Without Dampening Immune System
BioNTech’s experimental non-inflammatory vaccine — designed to dampen the abnormal immune responses seen in multiple sclerosis (MS) against…
Top 10 Multiple Sclerosis Stories of 2020
Multiple Sclerosis News Today brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to…
Dosing Finishes in Trial of NurOwn Cell Therapy for Progressive MS
Patient dosing has finished in a Phase 2 clinical trial testing NurOwn,…
Mayzent Aids Cognitive Processing Speed in SPMS Patients, Trial Suggests
Mayzent (siponimod) significantly improved cognitive processing speed in people with…
FDA Approves Shorter Infusion Time for MS Therapy Ocrevus
The U.S. Food and Drug Administration has approved a shorter infusion time of Ocrevus (ocrelizumab) for treating relapsing or…
Ublituximab Superior to Aubagio at Lowering Relapse Rates, Phase 3 Data Show
Ublituximab, an investigational anti-CD20 antibody, outperformed Aubagio (teriflunomide) in lowering the frequency of relapses among people with active,…
Inflammatory Environment in MS Impairs Myelin Debris-clearing by Immune Cells
The pro-inflammatory environment characteristic of multiple sclerosis (MS) reduces the levels of PPAR-gamma — a receptor protein whose activation dampens…
Mesenchymal Stem Cell Transplant With NG-01 Treatment Shows Promise in Progressive MS
Treatment with NG-01 — an approach that uses patients’ own mesenchymal stem cells (MSCs) — safely and effectively…
Virtual Reality-based Rehabilitation May Improve Upper Limb Function in MS Patients, Review Finds
Motor rehabilitation using virtual reality (VR) may improve hand and arm function in people with multiple sclerosis (MS), according to…